| Literature DB >> 35409009 |
Fan-Yu Hsu1, Jia-Ying Liou1, Feng-Yao Tang2, Nga-Lai Sou1,3, Jian-Hau Peng1,3,4, En-Pei Isabel Chiang1,3,4.
Abstract
Given the popularity of ketogenic diets, their potential long-term consequences deserve to be more carefully monitored. Mitochondrially derived formate has a critical role in mammalian one-carbon (1C) metabolism and development. The glycine cleavage system (GCS) accounts for another substantial source for mitochondrially derived 1C units.Entities:
Keywords: glycine cleavage system; ketogenic diet; medium-chain triglycerides; mitochondrial formate production; one-carbon metabolism; stable isotopic labeling experiments
Mesh:
Substances:
Year: 2022 PMID: 35409009 PMCID: PMC8998878 DOI: 10.3390/ijms23073650
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Proposed effects of ketogenesis on one-carbon metabolism. The conversion of β-hydroxybutyrate to acetoacetate reduces the reaction NAD+ to NADH, leading to increased NAD(P)+. KD—ketogenic diet; NAD+—nicotinamide adenine dinucleotide; NADP+—phosphorylated NAD+; NADH—reduced NAD+; NADPH—reduced NADP+; mTORC1—mechanistic target of rapamycin complex 1; ATF4—activating transcription factor 4; MTHFD2—the bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase; ALDH1L2—aldehyde dehydrogenase 1 family member L2; SHMT1—serine hydroxymethyltransferase 1; SHMT2—serine hydroxymethyltransferase 2; PHGDH—phosphoglycerate dehydrogenase; GCS—glycine cleavage system; THF—tetrahydrofolate; 5,10-CH2-THF—5,10-methylenetetrahydrofolate; 5,10-CH=THF—5,10-methenyltetrahydrofolate; 10-CHO-THF—10-Formyltetrahydrofolate; 5-CH3THF—5-methyltetrahydrofolate; DHF—dihydrofolate; dUMP—deoxyuridine monophosphate; dTMP—deoxythymidine monophosphate; Ser—serine; Gly—glycine; Met—methionine; Hcy—homocysteine; adoHcy—S-adenosyl-L-homocysteine; adoMet—S-adenosyl-L-methionine; 3PG—3-phosphserine.
Figure 2In vivo experimental design for investigation of ketogenesis on 1C metabolic fluxes. Body weight, energy intake, and feeding efficiency over the 8-week dietary intervention are shown. (A) Study design. After 1 week of habituation, mice were divided into 2 groups and fed with either a control diet (CTL) or a medium-chain enriched triglyceride ketogenic diet (MCT-KD) for 8 weeks. The 2 pie charts present the diet compositions of macronutrients. Ketone measurements were taken 4 weeks after diet intervention. (B) The mean energy intake of MCT-KD-fed mice was greater than that of the mice fed the (CTL) diet. (C) The body weight changes during the intervention period. The mean body weight of MCT-KD-fed mice became significantly lower 30 days after the initiation of the diet intervention. (D) The feeding efficiency was calculated as the total body mass gain divided by total kcal for each individual animal over the duration of the study. Feeding efficiency of MCT-KD was significantly lower than the CTL diet. For (B–D), data values represent group means (±SEM, MCT-KD, 12/group, * p < 0.05 vs. CTL, ** p < 0.01 vs. CTL).
Effect of medium-chain triglyceride enriched ketogenic diet (MCT-KD) on body weight, body fats, muscle mass, and blood ketone concentrations 1.
| βHB 3 (mM) | BW 3 (g) | BAT/BW 3 | VAT/BW 3 | RAT/BW 3 | Muscle/BW 3 | |
|---|---|---|---|---|---|---|
| CTL 2 | 0.37 ± 0.11 | 27.64 ± 2.3 | 0.003 ± 0.001 | 0.005 ± 0.003 | 0.02 ± 0.009 | 0.010 ± 0.001 |
| MCT-KD 2 | 0.58 ± 0.16 | 25.48 ± 1.2 | 0.002 ± 0.000 | 0.001 ± 0.000 | 0.01 ± 0.002 | 0.011 ± 0.001 |
| 0.009 | 0.014 | 0.039 | 0.0001 | 0.001 | 0.017 | |
| % change | +54% | −8% | −25% | −79% | −61% | +11% |
1 Values are presented as mean ± SD (CTL n = 8; MCT-KD n = 12). Data are calculated by Student’s t-test. 2 CTL—the control group; MCT-KD—MCT-enriched ketogenic diet group. 3 βHB—β-hydroxybutyrate; BW—body weight; BAT/BW—brown adipose tissue normalized to body weight; RAT/BW—reproductive adipose tissue normalized to body weight; VAT/BW—visceral adipose tissue normalized to body weight; muscle/BW—skeletal muscle from gastrocnemius muscle normalized to body weight.
Plasma formate concentration and formate carbon flow from isotopic tracer L-[2,3,3-2H3]-Serine and [2-13C]-Glycine.
| Serine 1 | Glycine 1 | Formate 1 | Formate + 1 from | Formate + 1 from | |
|---|---|---|---|---|---|
| CTL 4 | 180 ± 36 | 584 ± 149 | 27.0 ± 7.0 | 0.023 ± 0.002 | 0.002 ± 0.001 |
| MCT-KD 4 | 214 ± 158 | 764 ± 244 | 21.7 ± 7.1 | 0.014 ± 0.001 | Undetectable |
| % change 3 | +31% # | −19% # | −38% | −100% |
1 Plasma samples were extracted and analyzed for measuring the amino acid and formate concentrations (n = 8–12/group). These results are within mice’s normal range compared to the literature [22]. 2 Plasma formate enrichments in mice received L-[2,3,3-2H3]-Serine or [2-13C]-Glycine tracers (n = 2–3/group). 3 All values are presented as mean ± SD. Data are compared to the controls by Student’s t-test. The % change of each metabolite or the isotopic enrichments in each target compound was calculated by comparing it to that of the control group. Data with a % change shown in the table indicate statistically significantly compared to the controls (p < 0.05). Data with a % change shown with a indicate a trend of difference compared to the control (p < 0.1). 4 CTL—the control group; MCT-KD—MCT-enriched ketogenic diet group.
Ketone body and ketogenic state due to consumption of medium-chain triglyceride enriched ketogenic diet (MCT-KD) inhibited deoxythymidine synthesis (dTMP) derived from formate via mitochondrial glycine cleavage system in vitro and in vivo 1.
| (A) BHB at 10 mM Inhibited dTMP Synthesis and Purine Synthesis from [2-13C]-Glycine In Vitro 1 | |||||||
| From direct incorporation into DNA | From GCS derived formate | ||||||
| dA + 1 2 | dG + 1 2 | dA + 2 2 | dTMP + 1 2 | ||||
| CTL 3 | 0.323 ± 0.002 | 0.350 ± 0.003 | 0.011 | 0.027 ± 0.002 | |||
| BHB low 3 | 0.321 ± 0.010 | 0.340 ± 0.001 | 0.009 | 0.025 ± 0.001 | |||
| BHB high 3 | 0.253 ± 0.001 | 0.267 ± 0.018 | 0.000 | 0.012 ± 0.001 | |||
| % low BHB 4 | −3% # | ||||||
| % high BHB 4 | −22% | −24%% | −100 | −55% | |||
| (B) MCT-KD Inhibited the Utilization of GCS Derived Formate in Thymidine Synthesis in the Bone Marrow 1 | |||||||
| From direct incorporation into protein/DNA | From GCS derived formate | ||||||
| Ser + 1 2 | Gly + 1 2 | dA + 1 2 | dG + 1 2 | dTMP + 1 2 | Ser + 2 2 | Ser + 2/Gly + 1 2 | |
| CTL 5 | 0.046 ± 0.002 | 0.057 ± 0.001 | 0.085 ± 0.008 | 0.089 ± 0.013 | 0.011 ± 0.001 | 0.0008 ± 0.000 | 0.015 ± 0.003 |
| MCT-KD 5 | 0.049 ± 0.003 | 0.051 ± 0.003 # | 0.072 ± 0.001 | 0.081 ± 0.001 | 0.008 ± 0.000 | 0.0001 ± 0.000 | 0.002 ± 0.001 |
| % change 4 | 4% | −12% # | −16% | −9% # | −25% # | −85% | −83% # |
| (C) MCT-KD Inhibited the Utilization of GCS Derived Formate on Synthesizing Serine in the Liver 1 | |||||||
| From direct incorporation into protein/DNA | From GCS derived formate | ||||||
| Ser + 1 2 | Gly + 1 2 | Ser + 1 2 | Gly + 1 2 | Ser + 1 2 | |||
| CTL 5 | 0.088 ± 0.005 | 0.070 ± 0.005 | 0.034 ± 0.005 | 0.058 ± 0.006 | 0.002 ± 0.000 | 0.001 ± 0.000 | 0.019 ± 0.002 |
| MCT-KD 5 | 0.078 ± 0.008 | 0.061 ± 0.016 | 0.025 ± 0.001 | 0.034 ± 0.002 | 0.002 ± 0.000 | undetectable | undetectable |
| % change 4 | −11% | −13% | −25% | −42% # | 12% | −100% | −100% |
1 Values are presented as mean ± SD (n = 2–3/group). Data are compared by Student’s t-test. 2 Ser + 1, serine enrichment; Gly + 1, glycine enrichment; dA + 1, deoxyadenosine enrichment; dG + 1, deoxyguanosine enrichment; dTMP + 1, deoxythymidine enrichment; Ser + 2, serine enrichment; Ser + 2/Gly + 1, the relative enrichment of serine from [2-13C]-Glycine. The enrichments in Ser + 1, Gly + 1, dA + 1, dG + 1, come from direct incorporation into protein/DNA. Enrichments in dTMP + 1 and Ser + 2 come from GCS derived formate from [2-13C]-Glycine. 3 CTL: control; BHB low: 1 mM β-Hydroxybutyrate dose in vitro; BHB high: 10 mM β-hydroxybutyrate dose in vitro. 4 The % change of the isotopic enrichments in each target compounds compared to the control group. Data with a % change shown in the table indicate statistically significantly compared to the controls (p < 0.05). Data with a % change shown with a # indicate a trend of difference compared to the control (p < 0.1). 5 CTL, controls; MCT-KD, MCT enriched ketogenic diet group.
Figure 3Effects of β-hydroxybutyrate (βHB) and MCT-KD consumption on the metabolic fate of glycine 2-carbon during glycine decarboxylation. The glycine cleavage system (GCS)-derived 1C moiety is exported from the mitochondria as formate. βHB inhibited mitochondrial formate generation from GCS in vitro. Ketogenic diet inhibited mitochondrial formate generation from GCS in mouse bone marrow. Abbreviations: GCS—glycine cleavage system; THF—tetrahydrofolate; 5,10-CH2-THF—5,10-methylenetetrahydrofolate; 5,10-CH=THF—5,10-methenyltetrahydrofolate; 10-CHO-THF—10-formyltetrahydrofolate; DHF—dihydrofolate; dUMP—deoxyuridine monophosphate; dTMP—deoxythymidine monophosphate; Ser—serine; Gly—glycine; Met—methionine; Hcy—homocysteine; adoHcy—S-adenosyl-L-homocysteine; adoMet—S-adenosyl-L-methionine; C—cytosine; mC—deoxy 5-methylcytosine; dA + 1—deoxyadenosine enrichments; dG + 1—deoxyguanosine; dTMP + 1—deoxythymidine; Ser + 1—serine enrichments; Gly + 1—glycine enrichments from [2-13C]glycine; Ser + 2—serine enrichments via mitochondria GCS.
Partitioning between mitochondrial and cytosolic 1C metabolic fluxes in thymidine biosynthesis 1,2.
| (A) Cell Model | ||||
| dTMP + 1 3 | dTMP + 2 3 | Total 3 | % Mito 3 | |
| CTL 4 | 0.295 ± 0.008 | 0.050 ± 0.000 | 0.345 ± 0.008 | 85% |
| βHB low 4 | 0.299 ± 0.012 | 0.049 ± 0.001 | 0.349 ± 0.012 | 86% |
| βHB high 4 | 0.296 ± 0.009 | 0.047 ± 0.001 | 0.343 ± 0.010 | 86% |
| % low βHB 4 | ||||
| % high βHB 4 | −7% # | |||
| (B) Mouse Bone Marrow DNA | ||||
| dTMP + 1 3 | dTMP + 2 3 | Total 3 | % Mito 3 | |
| CTL 3 | 0.086 ± 0.002 | 0.010 ± 0.00 | 0.096 ± 0.002 | 90% |
| MCT-KD 3 | 0.068 ± 0.005 | 0.008 ± 0.001 | 0.075 ± 0.005 | 90% |
| % change 2 | −21% # | −25% # | −22% # | |
| (C) Mouse Liver DNA | ||||
| dTMP + 1 3 | dTMP + 2 3 | Total 3 | % Mito 3 | |
| CTL 4 | 0.005 ± 0.000 | 0.0005 ± 0.000 | 0.005 ± 0.000 | 91% |
| MCT-KD 4 | 0.002 ± 0.000 | 0.0002 ± 0.000 | 0.003 ± 0.001 | 93% |
| % change 2 | −48% | −55% # | −49% | |
1 Cellular DNA from cells and mouse tissues was extracted and analyzed for the deoxythymidylate (dTMP) synthesis using L-[2,3,3-2H3]serine as the tracer. 2 Values are presented as mean ± SD (n = 2–3/group) and compared by Student’s t-test. The % change of the isotopic enrichments in each target compound was calculated by comparing them to the control group. Data with a % change shown in the table indicate statistically significantly compared to the controls (p < 0.05). Data with a % change shown with a # indicate a trend of difference compared to the control (p < 0.1). 3 The dTMP + 1 enrichments from L-[2,3,3-2H3]serine reflected the 1C moiety from mitochondrial formate; the dTMP + 2 enrichments from L-[2,3,3-2H3]serine reflected the utilization of cytosolic 1C via cSHMT; Total, total enrichments of dTMP from both mitochondrial and cytosol formate; % Mito was calculated from dTMP + 1 and dTMP + 2 that represents the fractional mitochondrial formate supply for dTMP synthesis. 4 CTL—the control group; βHB low, cells were treated with 1 mM β-hydroxybutyrate; βHB high, treated with 10 mM β-hydroxybutyrate; MCT-KD—MCT-enriched ketogenic diet group.
Fractional mitochondrial formate supply for methionine synthesis in vivo 1,2.
| (A) in Plasma Free Amino Acid | ||||
| Met + 1 3 | Met + 2 3 | Total | % Mito 2 | |
| CTL 4 | 0.011 ± 0.000 | 0.003 ± 0.000 | 0.016 ± 0.000 | 80% ± 2% |
| MCT-KD 4 | 0.013 ± 0.003 | 0.002 ± 0.002 | 0.014 ± 0.005 | 88% ± 12% |
| (B) in Liver Cellular Protein | ||||
| Met + 1 3 | Met + 2 3 | Total | % Mito 2 | |
| CTL 4 | 0.012 ± 0.001 | 0.004 ± 0.000 | 0.017 ± 0.002 | 74% ± 1% |
| MCT-KD 4 | 0.006 ± 0.001 | 0.005 ± 0.002 | 0.011 ± 0.003 | 57% ± 4% |
| % change 3 | −48% # | −35% # | −23% | |
| (C) in Bone Marrow Cellular Protein | ||||
| Met + 1 2 | Met + 2 2 | Total | % Mito | |
| CTL 4 | 0.019 ± 0.001 | 0.007 ± 0.001 | 0.026 ± 0.002 | 75% ± 3% |
| MCT-KD 4 | 0.018 ± 0.001 | 0.006 ± 0.000 | 0.024 ± 0.002 | 75% ± 0% |
1 Cellular proteins from mouse tissues were extracted and analyzed for the methionine synthesis using L-[2,3,3-2H3]serine as the tracer. 2 Values are presented as mean ± SD (n = 2–3/group) and compared by Student’s t-test. The % change of the isotopic enrichments in each target compound was calculated by comparing them to the control group. 3 Met + 1—methionine enrichment from mitochondrial formate; Met + 2—methionine enrichment using cytosolic one-carbon unit from L-[2,3,3-2H3]serine; Total—total enrichments of methionine from both mitochondrial and cytosol formate; % Mito was calculated from Met + 1 and Met + 2 that represents the fractional mitochondrial formate supply for methionine synthesis. Data with a % change shown in the table indicate statistically significantly compared to the controls (p < 0.05). Data with a % change shown with a # indicate a trend of difference compared to the control (p < 0.1). 4 CTL—the control group; MCT-KD—MCT-enriched ketogenic diet group.
Utilization of L-[2,3,3-2H3]serine and serine to glycine conversion in vivo 1,2.
| (A) Plasma | ||||||
| Leu + 1 + 2 + 3 1 | Ser + 1 + 2 + 3 3 | Ser + 1 3 | Ser + 2 3 | Ser + 3 3 | Gly + 1 3 | |
| CTL 4 | 0.089 ± 0.000 | 0.042 ± 0.005 | 0.012 ± 0.002 | 0.020 ± 0.003 | 0.010 ± 0.001 | 0.003 ± 0.001 |
| MCT-KD 4 | 0.089 ± 0.002 | 0.08 ± 0.019 | 0.022 ± 0.004 | 0.040 ± 0.009 | 0.017 ± 0.006 | 0.004 ± 0.001 |
| % change 3 | +91% # | +90% # | +101% # | |||
| (B) Liver Protein | ||||||
| Leu + 1 + 2 + 3 1 | Ser + 1 + 2 + 3 3 | Ser + 1 3 | Ser + 2 3 | Ser + 3 3 | Gly + 1 3 | |
| CTL 4 | 0.099 ± 0.002 | 0.190 ± 0.035 | 0.046 ± 0.009 | 0.075 ± 0.003 | 0.069 ± 0.030 | 0.022 ± 0.006 |
| MCT-KD 4 | 0.069 ± 0.007 | 0.143 ± 0.012 | 0.030 ± 0.007 | 0.067 ± 0.011 | 0.046 ± 0.006 | 0.005 ± 0.001 |
| % change 3 | −30% # | −76% # | ||||
| (C) Bone Marrow Protein | ||||||
| Leu + 1 + 2 + 3 1 | Ser + 1 + 2 + 3 3 | Ser + 1 3 | Ser + 2 3 | Ser + 3 3 | Gly + 1 3 | |
| CTL 4 | 0.110 ± 0.002 | 0.0196 ± 0.012 | 0.054 ± 0.003 | 0.073 ± 0.002 | 0.069 ± 0.006 | 0.039 ± 0.004 |
| MCT-KD 4 | 0.101 ± 0.001 | 0.200 ± 0.018 | 0.050 ± 0.003 | 0.079 ± 0.008 | 0.070 ± 0.007 | 0.029 ± 0.003 |
| % change 3 | −8% # | −27% # | ||||
1 Mouse plasma and tissues were extracted and analyzed for the serine and glycine conversion and the isotopic distributions from [2,3,3-2H3]serine. Protein turnover was estimated by leucine tracer. 2 Values are presented as mean ± SD (n = 2–3/group) and compared by Student’s t-test. The % change of the isotopic enrichments in each target compound was calculated by comparing them to the control group. The % change is presented when values are statistically significant (bold) or with a trend (p < 0.1) of difference from controls (italic). 3 Putative isotopic enrichment of serine + 3: [2,3,3-2H3]serine (Ser + 3) is labeled with one deuterium atom at the C-2 and another two at C-3 position. The synthesis of 5,10-CH2THF acquires the methylene group (-CH2-) from serine, generating glycine. The deuterium atom in 5,10-CD2THF from cytosol via cSHMT and that from mitochondria-derived formate (CDOOH). In the reverse reaction, [2,3,3-2H3]serine can be synthesized from [2-2H1] glycine with the incorporation of the labeled methylene group of 5,10-CD2THF from cytosol. Putative isotopic enrichment of serine + 1: continued from above reaction, but in the reverse reaction, [2-2H1] serine (Ser + 1) is synthesized from [2-2H1] glycine with the incorporation of an unlabeled methylene group from 5,10-CH2THF, via cSHMT. Alternatively, [3-2H1]serine (Ser + 1) can be synthesized from unlabeled glycine with the incorporation of the labeled methylene group of 5,10-CDHTHF from mitochondria-derived formate. Gly + 1, glycine enrichment from L-[2,3,3-2H3]serine. Data with a % change shown with a # indicate a trend of difference compared to the control (p < 0.1). 4 CTL—the control group; MCT-KD—MCT-enriched ketogenic diet group.
Partitioning of 5-methylTHF dependent methionine synthesis and 5,10 methylene THF dependent dTMP synthesis from L-[2,3,3-2H3]serine 1,2.
| (A) The Methionine Synthesis from L-[2,3,3-2H3]serine in Plasma 1 | ||||
| Ser + 1 + 2 + 3 1 | Met + 1 + 2 3 | FDR 3 | ||
| CTL 5 | 0.042 ± 0.005 | 0.016 ± 0.000 | 39.6 ± 4.9% | |
| MCT-KD 5 | 0.08 ± 0.019 | 0.014 ± 0.005 | 16.3 ± 2.9% | |
| % change 3 | +91% | −23% | ||
| (B) Methionine Synthesis from L-[2,3,3-2H3]serine in Liver Cytoplasm | ||||
| Ser + 1 + 2 + 3 4 | Met + 1 + 2 4 | FDR 5 | ||
| CTL 5 | 0.149 ± 0.045 | 0.016 ± 0.006 | 10.9 ± 0.4% | |
| MCT-KD 5 | 0.104 ± 0.013 | 0.017 ± 0.004 | 17.6 ± 5.7% | |
| (C) Utilization of L-[2,3,3-2H3]serine in Liver Protein Methionine and DNA | ||||
| via 5-methylTHF | via 5,10 methylene THF | |||
| Met + 1 + 2 4 | FDR 5 | dT + 1 + 2 4 | dT from Ser 4 | |
| CTL 5 | 0.017 ± 0.002 | 9.2 ± 2.7% | 0.0052 ± 0.000 | 2.9 ± 0.66% |
| MCT-KD 5 | 0.011 ± 0.003 | 7.8 ± 1.6% | 0.0026 ± 0.001 | 1.8 ± 0.66% |
| % change 3 | −32% | −16% | −53% # | −34% |
| (D) Methionine Synthesis from L-[2,3,3-2H3]serine in Bone Marrow Cytoplasm | ||||
| Ser + 1 + 2 + 3 4 | Met + 1 + 2 4 | FDR 4 | ||
| CTL 5 | 0.196 ± 0.012 | 0.029 ± 0.009 | 41.5 ± 24.2% | |
| MCT-KD 5 | 0.200 ± 0.018 | 0.017 ± 0.000 | 28.5 ± 2.1% | |
| % change 3 | −12% # | |||
| (E) Utilization of L-[2,3,3-2H3]serine in Marrow Protein and DNA | ||||
| via 5-methylTHF | via 5,10 methylene THF | |||
| Met + 1 + 2 4 | FDR 5 | dT + 1 + 2 4 | dT from Ser 4 | |
| CTL 5 | 0.023 ± 0.001 | 11.9 ± 0.2% | 0.096 ± 0.002 | 122.8 ± 38.7% |
| MCT-KD 5 | 0.020 ± 0.001 | 10.2 ± 0.2% | 0.075 ± 0.005 | 124.6 ± 18% |
| % change 3 | −1.7% | −22% # | ||
| (F) Partitioning of 5,10 MethyleneTHF between Methionine and dTMP Thymidylate Synthesis in the Liver 4 | ||||
| mito 1C Met/dTMP 4 | cyto 1C Met/dTMP 4 | Total met/dTMP | ||
| CTL 5 | 2.593 ± 0.199 | 0.111 ± 0.002 | 0.316 ± 0.019 | |
| MCT-KD 5 | 2.723 ± 0.927 | 0.069 ± 0.069 | 0.270 ± 0.138 | |
| (G) Partitioning of 5,10 MethyleneTHF between Methionine and dTMP Thymidylate Synthesis in the Bone Marrow 4 | ||||
| mito 1C Met/dTMP 4 | cyto 1C Met/dTMP 4 | Total met/dTMP | ||
| CTL 5 | 0.238 ± 0.015 | 6.226 ± 4.018 | 4.143 ± 0.093 | |
| MCT-KD 5 | 0.232 ± 0.01 | 1.717 ± 0.255 | 3.717 ± 0.000 | |
1 Mouse tissues were extracted and analyzed for the partitioning between 5-methylTHF-dependent methionine synthesis and 5,10 methylene THF-dependent dTMP synthesis from L-[2,3,3-2H3]serine. 2 Values are presented as mean ± SD (n = 2–3/group) and compared by Student’s t-test. The % change of the isotopic enrichments in each target compound was calculated by comparing them to the control group. The % change is presented when values are statistically significant (bold with *) or with a trend (p < 0.1) of difference from controls (italic with #). 3 Met + 1—methionine enrichment from mitochondrial formate; Met + 2—methionine enrichment using cytoplasmic one-carbon unit from L-[2,3,3-2H3]serine; Total—total enrichments of methionine from both mitochondrial and cytosol formate; % Mito was calculated from Met + 1 and Met + 2 that represents the fractional mitochondrial formate supply for methionine synthesis. FDR, folate-dependent remethylation of homocysteine, calculated by enrichments of methionine and serine. Data with a % change shown in the table indicate statistically significantly compared to the controls (p < 0.05). Data with a % change shown with a # indicate a trend of difference compared to the control (p < 0.1). 4 Partitioning of 5-methylTHF dependent methionine synthesis and 5,10 methylene THF dependent dTMP synthesis in mitochondria was calculated using dTMP + 1 and Met + 1; partitioning of 5-methylTHF dependent methionine synthesis and 5,10 methylene THF dependent dTMP synthesis in cytosol was calculated using dTMP + 2 and Met + 2. dT from Ser, the thymidine synthesis from serine was abbreviated as dT from Ser, and calculated as dT + 1 + 2/Ser + 1 + 2 + 3. 5 CTL—the control group; MCT-KD—MCT-enriched ketogenic diet group.
Figure 4Tracing the partitioning of 1 carbon flux between mitochondrial and cytosolic derived one-carbon moiety via L-[2,3,3-2H3]serine. L-[2,3,3-2H3]serine tracer enables distinguishing mitochondrial (shown in cyan M + 1) derived 1C moiety from cytosolic (blue M + 2) counterpart. On the lower right, generation of de novo [2H1]-thymidine from mitochondria-derived formate via mitochondrial serine hydroxymethyl-transferase (mSHMT) and de novo [2H2] thymidine from cytosol via cytosolic SHMT (cSHMT). On the lower left, generation of [2H1] methionine from mitochondrial-derived formate and [2H2] methionine from cytosol via cSHMT. Enrichments in target metabolites were determined to investigate the impacts of ketogenetic state on formate utilization for thymidine and methionine syntheses from mitochondria (cyan M + 1) and cytosol (blue M + 2). Denotes the labeled metabolites. * ** *** Denotes M + 1, M + 2, M + 3, respectively. MTHFD2—the bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase; ALDH1L2—aldehyde dehydrogenase 1 family member L2; SHMT1—serine hydroxymethyltransferase 1; SHMT2—serine hydroxymethyltransferase 2; GCS—glycine cleavage system; THF—tetrahydrofolate; 5,10-CH2-THF—5,10-Methylenetetrahydrofolate; 5,10-CH=THF—5,10-Methenyltetrahydrofolate; 10-CHO-THF—10-Formyltetrahydrofolate; DHF—dihydrofolate; 5-CH3THF—5-methyltetrahydrofolate; dUMP—deoxyuridine monophosphate; dTMP—deoxythymidine monophosphate; Ser—serine; Gly—glycine; Met—methionine; Hcy—homocysteine; adoHcy—S-adenosyl-L-homocysteine; adoMet—S-adenosyl-L-methionine; dA + 1—deoxyadenosine enrichments; dG + 1—deoxyguanosine; Gly + 1—glycine enrichment; Met + 1, Met + 2—methionine enrichment from mitochondrial-derived formate and 5-CH3THF; dT + 1, dT + 2—deoxythymidine enrichment; dT + 1 + 2—deoxythymidine enrichment from both mitochondrial-derived formate and 5,10-CH2-THF.
Figure 5In vivo and in vitro experimental design. (A) Mouse model. After 1 week of habituation, mice were divided into 2 groups and fed with either a control diet (CTL) or a medium-chain enriched triglyceride ketogenic diet (MCT-KD) for 8 weeks (n = 8 vs. 12). The 2 pie charts present the diet compositions of macronutrients. (B) The cell model for investigating the effects of β-hydroxybutyrate on glycine catabolism and mitochondrial-derived formate utilization. Abbreviations: CTL—control groups; MCT-KD—medium-chain enriched triglyceride ketogenic diet; α-MEM—essential medium alpha medium; βHB—β-hydroxybutyrate.
Diet composition of MCT enriched ketogenic diet and control (AIN-93M).
| Macronutrients | CTL (AIN-93M) | MCT-KD 1 |
|---|---|---|
| Protein, % of energy | 14.4% | 14.4% |
| Carbohydrate, % of energy | 75.4% | 0.0% |
| Fat % of energy | 10.2% | 85.6% |
| Energy, kcal/g | 3.60 | 5.89 |
| Casein | 140.0 | 140.0 |
| L-Cysteine | 1.8 | 1.8 |
| Sucrose | 100.0 | 0.0 |
| Cornstarch | 465.7 | 0.0 |
| Dyetrose | 155.0 | 0.0 |
| Soybean oil | 40.0 | 67.2 |
| MCT oil | 0 | 291.64 |
| Cellulose | 50 | 50 |
| Salt Mix #210053 | 35 | 35 |
| Vitamin Mix #310025 | 10 | 10 |
| Choline bitartrate | 2.5 | 2.5 |
1 CTL—the control diet; MCT-KD—MCT-enriched ketogenic diet.